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An understanding of the clinical aspects of electrical storm (E-storms) in patients with implantable
cardiac shock devices (ICSDs: ICDs or cardiac resynchronization therapy with deﬁbrillator [CRT-D]) may
provide important information for clinical management of patients with ICSDs. The Nippon Storm
Study was organized by the Japanese Heart Rhythm Society (JHRS) and Japanese Society of Electro-
cardiology and was designed to prospectively collect a variety of data from patients with ICSDs, with a
focus on the incidence of E-storms and clinical conditions for the occurrence of an E-storm. Forty main
ICSD centers in Japan are participating in the present study. From 2002, the JHRS began to collect ICSD
patient data using website registration (termed Japanese cardiac deﬁbrillator therapy registration, or
JCDTR). This investigation aims to collect data on and investigate the general parameters of patients
with ICSDs, such as clinical backgrounds of the patients, purposes of implantation, complications during
the implantation procedure, and incidence of appropriate and inappropriate therapies from the ICSD.
The Nippon Storm Study was planned as a sub-study of the JCDTR with focus on E-storms. We aim to
achieve registration of more than 1000 ICSD patients and complete follow-up data collection, with the
assumption of a 5–10% incidence of E-storms during the 2-year follow-up.
& 2012 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Background
Implantable cardioverter-deﬁbrillator (ICD) therapy is the
most effective therapy for reducing mortality in patients with a
high risk of life-threatening ventricular tachyarrhythmias [1–10].
However, ICDs cannot prevent the occurrence of tachycardia
attacks, and this limits the clinical usefulness of ICDs. Several
recent clinical trials have shown that patients who received
shocks from ICDs for any arrhythmia have a substantially higher
risk of death than similar patients who do not receive such shocks
[11,12]. Moreover, frequent, repeated shocks from an ICD due to
electrical storms (E-storms) have been recognized as an impor-
tant clinical factor causing deterioration of patient outcomes and
quality of life (QOL), but detailed clinical aspects of E-storms after
ICD implantation have not yet been investigated.rt Rhythm Society. Published by E
a).2. Purpose
An understanding of the clinical aspects of E-storms in
patients with implantable cardiac shock devices (ICSDs: ICDs or
cardiac resynchronization therapy with deﬁbrillator [CRT-D]) may
provide important information for clinical management of
patients with ICSDs. The Japanese Heart Rhythm Society (JHRS)
and Japanese Society of Electrocardiology (JSE) decided to colla-
borate in the Nippon Storm Study. This prospective study was
designed to collect a variety of data from patients with ICSDs,
with a focus on the incidence of E-storms and clinical conditions
that may promote the occurrence of E-storms. To the best of our
knowledge, this is the ﬁrst clinical trial that has been speciﬁcally
designed to evaluate E-storms in patients with ICSDs.3. Methods
Participating centers: Forty main ICSD centers in Japan from
Hokkaido to Okinawa, which cover approximately 20% of all new
ICSD patients in Japan, are participating in the present study.lsevier B.V. All rights reserved.
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years old) will be registered, regardless of their underlying heart
disease and regardless of the purpose (primary or secondary
prevention) for using an ICSD.
Data collection: From 2002, the JHRS began to collect ICSD patient
data using website registration (termed Japanese cardiac deﬁbrilla-
tor therapy registration, or JCDTR) [13]. This larger study aims to
collect data on and investigate the general parameters of patients
with ICSD, such as clinical backgrounds of patients (age, gender, and
underlying heart disease), purposes of indication (primary or sec-
ondary), complications during implantation procedures, and inci-
dence of appropriate and inappropriate therapies from the ICSD
(Table 1). Approximately 10,000 patients have been registered in
this trial [14]. The Nippon Strom Study was planned as a sub-study
of the JCDTR focus on E-storms after ICSD implantation.
All centers followed the national and international consensus
guidelines for implantation of an ICD, either in the ﬁeld of
secondary prevention or in the ﬁeld of primary prevention of
sudden death for all possible cardiac substrates [15,16].
To reduce workload of the medical staff at each institution,
registration for the study can be supported by a cardiac device
representative (CDR) who has passed the examination of Inter-
national Board of Heart Rhythm Examiners (IBHRE) and earnedTable 1
JCDTR and Nippon Storm Questionaire.
# Information on the implantation
1. Name of Institute, date of registry
2. Age and gender of the patient
3. Date of implantation
4. Names of the operators
5. Purpose of the implantation (primary or secondary)
6. Implantation indications on the basis of Japanese guidelines
7. Name of the implanted device
8. Implanted leads: atrium, ventricle 1, ventricle 2




VT, VF, torsade de pointes, syncope, unknown
2. Structural heart disease
3. Disease other than cardiac disease
4. NYHA classiﬁcation
5. LVEF, measurement method used
6. CAG
7. QRS duration and dyssynchrony
8. Signal-averaged ECG
9. Microvolt T wave alternans
10. Electrophysiologic study
11. Holter ECG
# Medication given at implantation
1. Antiarrhythmic drugs
2. Diuretics, ACE/ARB, etc.
3. Antiplatelets or anticoagulants
# Follow-up data
1. Date of follow-up
2. Documentation of event
Date and number of events, appropriate or inapropriate
3. Data at the event
(1) Change in programming (zone setting, threshold for rate
sensnig, etc.)
(2) ECG parameters (RR interval, QRS width, QT interval)
(3) Chest X-ray (CTR, congesiton)
(4) Biochemistry data (BNP, Na, K, Ca, Creatinine, BUN, etc.)
(5) Presense of heart failure
(6) Unscheduled admission
(7) Usage of antiarrhythmic drugs
(8) Survival at 1 week after electrical stomcertiﬁcation by demonstrating speciﬁc competence in cardiac
rhythm device therapy and cardiac electrophysiology. The major-
ity of technicians are employed by an ICSD company. A hardcopy
data sheet is ﬁlled out by medical staff (and/or by a CDR)
immediately after implantation of the ICD and is sent to the
secretary of the JHRS ofﬁce. The JHRS ofﬁce accesses the JCDTR
website (Nippon Storm Registration) and inputs the patient data
according to the prescribed documents. The JHRS secretary sends
an e-mail with the patients speciﬁc ID (UMIN ID) for this study to
the medical staff at each center, and they can then input
information for their own patient(s) on the website via their
personal computers. If errors or inconsistent data are found on a
data sheet, the JHRS secretary immediately contacts the medical
staffs at the center to obtain the correct information.
Follow-up data should be collected by each participating
center at a maximum interval of 6 months. At the outpatient
clinic, follow-up data are retrieved from the ICSD and written
down on the follow-up data sheets. The medical staff can also
request support from the CDR to complete these documents. The
data are also sent to the JHRS ofﬁce and submitted to the website
by the ofﬁce secretary. If a patient is using remote monitoring,
data can also be transmitted electronically [18].
For accurate collected of follow-up data, we have developed a
tracking system called ‘‘Chaser.’’ This system creates a schedule
sheet of the next patient’s visit to the hospital on the website.
The CDRs or hospital staff access the website and register the
information on the next scheduled visit. Chaser automatically
sends a message by e-mail with the patient’s schedule 7 day
before his or her visit. The CDR or medical staff will then be able
to prepare the follow-up data sheets before the patient’s visit.
When a patient accidentally cancels a medical check-up without
notiﬁcation, the CDR and medical staff should easily notice the
patient’s absence in the outpatient clinic, and they should make
an effort to determine the reason for the patient’s cancellation.
Using this system, we will be able to minimize loss of follow-
up data.
Since the data are provided via traditional or electronic mail
using only the speciﬁc ID without the patient’s name, personally
identiﬁable information must be protected.
Deﬁnition of E-storm: An E-storm was deﬁned as 3 or more
independent episodes that require appropriate ICD interventions
(either antitachycardia pacing or shock therapy) to terminate the
VT/VF within 24 h [17]. At least 3 apparent atrial conducted beats
after ICD intervention are required to be recognized as successful
termination of the VT/VF; in other words, if there are 3 or more
atrial conducted beats and/or back-up pacing between the 2 con-
secutive VT/VF episodes, these are counted as ‘‘2 episodes’’. With
the aim of excluding inappropriate multiple therapy of an ICD
from data analysis, electrocardiograms during the storm will be
sent to the JHRS secretary and will be evaluated by several
specialists in electrophysiology who do not participate in Nippon
Storm registration.
Data sample size: We aim to collect data for a large number of
patients with ICSDs within the 27-month registration period,
during which we expect to achieve registration of more than
1000 patients with ICSD and complete follow-up data collection
according to previous implant performance at each center with
the assumption of a 5–10% incidence of E-storms during the
2-year follow-up [19,20]. We will thus be able to obtain data for
50–100 cases of E-storms, and this large number of E-storm
events will allow us to investigate the clinical proﬁles of patients
who experience E-storms and the mechanism of E-storms.
Data collection began in October 2010, after the ethical aspects of
this study had been approved by the ethics committees at each
center. The patients will be followed up for at least 2 years.
Registration of new patients will be terminated in December 2014.
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All patients will be prospectively followed by participating
centers with a maximum follow-up interval of 6 months. Patient
data will be collected at ICSD outpatient clinics.
The primary endpoint is the occurrence of an E-storm within the
2-year follow-up period. To search for factors (baseline character-
istics) inﬂuencing the occurrence of an E-storm, we will implement
multivariate analysis using the Poisson regression model.
The secondary endpoint is the time to the ﬁrst occurrence of an
E-storm. The Kaplan–Meier method will be applied to estimate the
cumulative probability at each time point. In addition, we will
implement multivariate analysis using the Cox proportional hazard
model to search for factors inﬂuencing the time to the ﬁrst
occurrence. Similar analyses will be carried out to investigate other
events (death, heart failure, and unscheduled hospitalization).Role of the funding source
The Nippon Storm Study was organized by the JHRS and JSE
and is partly supported by the Japanese Heart Foundation and
Japanese Device Industry Association. There is no particular
sponsor (device product company) that has had a role in the
study design or conduct of the study, collection of data, analysis
or interpretation of data, or preparation of the present manu-
script. The corresponding author had full access to all of the data
and takes full responsibility for the integrity of the data in this
study as well as for the decision to submit this manuscript for
publication.Conﬂict of interest
There is no constrict of interest concerened with this sudy for
all authors.
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